dapirolizumab
UCB Pharmaceuticals
['lupus']
#eular2023 #pos0115 can we minimise placebo response in #lupus trials? post-hoc analysis of phase 2 rct dapirolizumab (cd40-cd40l-i) showed greater response in acute flare with normal complement levels in the pbo group. could low complement be used for trial entry? 
Rheumatologist. Interested in B-cells, Lupus, Sjogren, Pre-Connective Tissue Disease, Tennis, Running & Travelling 🌏